All
FDA Grants Regular Approval to Padcev for Pretreated Metastatic or Advanced Bladder Cancer
July 9th 2021Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.